S 18204

Drug Profile

S 18204

Latest Information Update: 22 Sep 1998

Price : $50

At a glance

  • Originator Servier
  • Class Antihyperglycaemics; Antiplatelets
  • Mechanism of Action Thromboxane A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetic nephropathies; Thrombosis

Most Recent Events

  • 22 Sep 1998 No-Development-Reported for Thrombosis in France (Unknown route)
  • 03 Aug 1998 No-Development-Reported for Diabetic nephropathies in France (Unknown route)
  • 14 May 1996 Preclinical development for Diabetic nephropathies in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top